First detection of High pathogenicity Avian #Influenza #H5N1 Clade 2.3.4.4b Genotype EA-2024-DI.2.1 in #Egypt associated with migratory wild birds

 

Abstract

High pathogenicity avian influenza (HPAI) H5 clade 2.3.4.4b is the main driver of the ongoing unprecedented global panzootic. The recently emerged HPAI H5N1 clade 2.3.4.4b genotype EA-2024-DI.2.1 has become predominant in Europe, with migratory wild birds, particularly waterfowl, playing a major role in its dissemination. Egypt lies along major Afro-Eurasian migratory flyways, which have historically played an important role in the introduction of emerging H5Nx viruses into the country. In this study, targeted surveillance was conducted on 416 wild birds offered for sale in in live bird markets (LBMs) and roadside trading points in northern Egypt, mainly in Damietta and Port Said. Of these, 118 birds showing mild clinical signs were examined post-mortem and lung and tracheal tissues were collected, while oropharyngeal and cloacal swabs were collected from apparently healthy birds. Avian influenza virus was detected by RT-qPCR in 22 wild birds, all from tissue samples, whereas all swabs from apparently healthy birds were negative. Waterfowl accounted for 16 of the 22 positive birds (72.7%), with Eurasian teal showing the lowest Ct values (21-25). Phylogenetic and whole-genome analyses showed that the sequenced wild-bird viruses clustered within the recently emerged EA-2024-DI.2.1 sub-lineage and were closely related to contemporary European viruses. Compared with the EA-2021-AB genotype currently circulating in Egyptian poultry, the EA-2024-DI.2.1 viruses showed several HA amino acid differences, including A83D, L104M and T195A. These findings provide evidence for the introduction of EA-2024-DI.2.1 into Egypt through migratory wild birds and highlight the importance of continued genomic surveillance at the wild bird domestic poultry interface and antigenic evaluation against vaccines currently used in Egypt.

Competing Interest Statement

The authors have declared no competing interest.

Funder Information Declared

the British Council International Science Partnerships Fund (ISPF), UK, grant number 1203757062

the Science, Technology & Innovation Funding Authority (STDF), Egypt., project ID 50185

Source: 

Link: https://doi.org/10.64898/2026.09.12.750890

____

A Decade of Chronic #Hepatitis E #Treatment: #Ribavirin Effectiveness, Safety, and the Association of Torque Teno Virus Load With Treatment Outcomes

 

Highlights

    • Ribavirin achieved 81% SVR in immunocompromised patients with chronic HEV.

    • Adverse events occurred in 56% and led to discontinuation in 17%.

    • Ribavirin dose reduction was associated with failure to achieve SVR.

    • Higher baseline HEV RNA levels were associated with non-SVR.

    • Baseline TTV load showed a nonsignificant trend toward higher levels in non-SVR patients.

Abstract

Background

Hepatitis E virus (HEV) affects immunocompromised individuals. Unlike immunocompetent hosts, who rarely develop chronic infection, up to two-thirds of immunocompromised patients progress to chronicity. Ribavirin is the recommended antiviral therapy, yet predictors of sustained virological response (SVR) remain unclear. Torque Teno Virus (TTV), a marker of immunosuppression, has been proposed as a potential predictor of viral clearance.

Objectives

We evaluated ribavirin treatment outcomes and adverse effects in immunocompromised patients with HEV infection, and assessed whether TTV load predicts SVR.

Study Design

A retrospective cohort study was conducted at the University Medical Center Groningen including solid organ transplant recipients (SOTR) and haematology patients treated with ribavirin for HEV infection between 2010 and 2022. Clinical data and stored serum samples were analysed to determine infection duration and TTV load at treatment initiation and after three months. TTV loads in treated patients were compared with TTV loads of transplant recipients who spontaneously cleared HEV.

Results

Fifty-two patients received ribavirin; 27 had confirmed chronic infection. SVR was achieved in 81% of chronic cases. Adverse events occurred in 56%, leading to dose reduction in 25% and discontinuation in 17%. Non-SVR was associated with ribavirin dose reduction, lower mean daily dose, higher baseline HEV RNA, and lower ALT. Baseline TTV load showed a nonsignificant trend toward higher levels in non-SVR patients. TTV loads did not differ between treated patients and spontaneous clearers.

Conclusions

Ribavirin is effective for chronic HEV, but treatment-limiting toxicity is common. Adequate dosing appears critical for achieving SVR. TTV load did not reliably predict treatment outcome, underscoring the need for further research into immunological and virological predictors of response.

Source: 

Link: https://doi.org/10.1016/j.jcv.2026.106003

_____

Detection of Highly Pathogenic Avian #Influenza #H5N1 Virus in #Cat and #Rats during #Outbreak in Backyard #Poultry, #USA, 2025

 

Abstract

In 2025, highly pathogenic avian influenza A(H5N1) virus was detected in a poultry flock in Illinois, USA. Quantitative reverse transcription PCR, sequencing, and histopathology on cat and rat samples from the farm showed multiple positive tissues and high sequence identity to an avian isolate. Small mammals might contribute to H5N1 transmission.

Source: 

Link: https://doi.org/10.3201/eid3210.260418

____

#Host type governs #influenza evolutionary #strategy across reservoir and #spillover hosts

 

Abstract

Despite its high propensity for host switching, the evolutionary mechanisms underlying influenza host adaptation remain unclear. H3Nx influenza viruses are uniquely generalist, with long-term lineages that circulate in avian, human, swine, equine, and canine hosts. Using 13,295 H3Nx sequences, we quantified host-specific adaptive evolution and developed a pipeline to map reassortment events onto trees with measures of statistical uncertainty. We find that while H3Nx viruses in mammals undergo adaptive evolution in HA and NA, viruses in birds experience very little directional selection. Instead, avian lineages exhibit high rates of reassortment, frequently generating novel reassortant lineages that persist transiently and turn over rapidly. 29.8-47.4% of all avian reassortant lineages are purged within the first year of circulation, and reassortment shows no fitness benefit in birds. In contrast, reassorted lineages in swine are more likely to persist long-term, suggesting that reassortment in swine may be broadly beneficial. Segment-specific reassortment patterns were also distinct between avian and mammalian viruses, with NA reassorting more frequently than expected in birds, but less frequently than expected in swine. Reassortment events are enriched between mammalian, but not avian, host switches, suggesting that reassortment may be most beneficial for mediating host switches among mammalian species. Together, our data suggest that host differences drive fundamentally different evolutionary outcomes for influenza viruses, transitioning from reassortment-dominant evolution in their avian reservoir, to varying degrees of adaptation upon establishment in mammals.

Competing Interest Statement

The authors have declared no competing interest.

Funder Information Declared

Pew Charitable Trusts

Margaret Q. Landenberger Research Foundation

National Institute of Allergy and Infectious Diseases

National Institutes of Health

Department of Health and Human Services

United States Department of Agriculture

Agricultural Research Service

Source: 

Link: https://www.biorxiv.org/content/10.64898/2026.09.15.751820v1

____

Detection of #Divergent Highly Pathogenic Avian #Influenza #H5N1 Clade 2.3.4.4b Virus, São Paulo, #Brazil, 2025

 

Abstract

In 2025, we detected highly pathogenic avian influenza H5N1 virus in dead waterfowl at Ibirapuera Park, São Paulo, Brazil. Genomic characterization indicated a reassortant virus that emerged from locally circulating low pathogenicity avian influenza viruses and highly pathogenic North American lineages. Our results highlight cross-species transmission risk and underscore the need for enhanced surveillance.

Source: 

Link: https://doi.org/10.3201/eid3210.260723

____

Estimated #Transmissibility and #CFR of #Bundibugyo Virus, #Uganda, 2007

 

Abstract

Because the epidemiology of Bundibugyo virus remains unclear, we reanalyzed the first recognized outbreak (Uganda, 2007). Adjusting for case under-ascertainment and the effect of control measures, we estimated the effective reproduction number (1.55, falling to <1 after intervention) and case-fatality rate (31%, declining to 25%). The underascertainment rate was 15%.

Source: 

Link: https://doi.org/10.3201/eid3210.261175

____

Experimental Highly Pathogenic Avian #Influenza #H5N1 Clade 2.3.4.4b Virus #Infection in #Alpacas, 2026

 

Abstract

Highly pathogenic avian influenza (HPAI) A(H5N1) clade 2.3.4.4b virus continues to spread globally and sporadically transmits from avian reservoirs to mammalian hosts. In May 2024, H5N1 infections in young goats and alpacas in the United States were reported. Nevertheless, the overall susceptibility of camelids to clade 2.3.4.4b virus remains unclear. We conducted a controlled experimental infection study in 6 alpacas, assessing clinical signs, viral shedding, tissue distribution, and serologic responses after intranasal inoculation with HPAI H5N1 genotype B3.13 virus. Observed illness was generally mild; body temperature increased slightly and food intake reduced for up to 3 days postinfection. We detected viral RNA in nasal swab samples and confirmed infectious HPAI H5N1 virus. Immunohistochemistry and RNA in situ hybridization detected virus only in the nasopharyngeal tonsil and nasal conchae at 4 days postinfection. Our findings suggest alpacas are susceptible to productive H5N1 infection, highlighting implications for livestock surveillance and biosecurity in regions with ongoing circulation.

Source: 

Link: https://doi.org/10.3201/eid3210.260491

____

Near real-time data on the #human neutralizing #antibody #landscape to #influenza virus in summer of 2026 shows antigenic advance of #H3N2 subclade K region D mutants and #H1N1 D.3.1.1 Sa mutants

 

Abstract

Human seasonal influenza evolves rapidly, necessitating twice yearly decisions about whether to update the strains in the vaccine. To help inform this decision, we have been using high-throughput sequencing-based neutralization assays to make twice yearly measurements of how recent human sera neutralize current human H3N2 and H1N1 strains. Here we provide the third installment in this series of measurements by reporting 47,851 titers representing neutralization of 148 viral strains by 325 human sera collected between April and August of 2026. Our measurements show that new H3N2 subclade K strains with mutations in antigenic region D and new H1N1 subclade D.3.1.1 strains with mutations in antigenic region Sa (such as G155E) have reduced neutralization by human sera, with notable heterogeneity in the impact of some of these mutations across sera from different individuals. This paper is accompanied by an interactive summary (https://jbloomlab.github.io/flu-seqneut-2026/summary.html) that enables detailed exploration of the results, and all titer data are publicly available for further analysis to aid vaccine antigen selection and studies of viral evolution.

Competing Interest Statement

JDB consults for Pfizer, GSK, Apriori Bio, and Merck. JDB has received stock options in the Vaccine Company. JDB is an inventor on Fred Hutch licensed patents related to techniques to characterize the antigenic effects of viral variation. SEH is a co-inventor on patents that describe the use of nucleoside-modified mRNA as a vaccine platform. SEH reports receiving consulting fees from Sanofi, Pfizer, Lumen, Novavax, and Merck. ALG reports contract testing to UW from Abbott, Cepheid, Novavax, Pfizer, Janssen, Assembly Biosciences, Aicuris, Innovative Molecules, and Hologic, research support from Gilead, personal consulting fees from Arisan Therapeutics, outside of the described work. JAE reports support to her institution from GSK, Pfizer, Moderna, and is a consultant for GSK, Pfizer, Merck, Meissa vaccines, Moderna, and Shionogi. ST reports research funding from Pfizer for a separate study.

Funder Information Declared

National Institute of Allergy and Infectious Diseases, R01AI165821, F30AI186284, 75N93021C00015

Howard Hughes Medical Institute, https://ror.org/006w34k90

Source: 

Link: https://doi.org/10.64898/2026.09.15.751855

____

Human #Adenovirus B3–Induced Immune #Thrombocytopenia and #Thrombosis

 

{Extract}

(...)

We report here the case of a previously healthy 12-year-old boy in whom virus-induced immune thrombocytopenia and thrombosis developed approximately 1 week after the onset of respiratory infection symptoms. Immune thrombocytopenia was suspected, and prednisolone therapy (30 mg daily) was started at the referring hospital. 

(...)

Source: 

Link: https://www.nejm.org/doi/full/10.1056/NEJMc2605960?query=TOC

____

Increased #receptor #binding and #spike glycosylation, remodeled immune #escape of surging #SARS-CoV-2 subvariant BA.3.2.2/RE.2.2/Cicada

 

Significance

SARS-CoV-2 evolved into distinct phylogenetic clades, generating a series of mutant strains. Notably, variants such as BA.1, BA.2.86, and BA.3.2 deserve special attention as they emerged abruptly at high detection frequencies during specific periods and harbored extensive mutations in the spike protein relative to contemporaneously prevalent strains, often accompanied by unique phenotypic characteristics. In this study, we primarily evaluated the structural and functional features of the BA.3.2.2 S protein, revealing its distinct traits in receptor binding, immune evasion, cross-species transmission, and glycosylation evolution. We observed constrained viral immune escape, as certain antibodies that were nonneutralizing against previously dominant subvariants exhibited neutralizing activity against recently emerged BA.3.2.2. These findings provide mechanistic insights for viral surveillance, vaccines, and therapeutics development.

Abstract

SARS-CoV-2 continues to evolve. The subvariant BA.3.2 (Cicada), a derivative of the Omicron BA.3 subtype first detected in late 2024, harbors multiple spike protein mutations, ORF7 and ORF8 deletions, and has recently evolved sublineages (BA.3.2.1 and BA.3.2.2), rendering it a critical target for epidemiological surveillance. The BA.3.2.2 sublineage, represented by RE.2.2, shows a marked upward trend in late 2025. Using surface plasmon resonance, we found that RE.2.2’s spike (S) protein receptor-binding domain (RBD) exhibits relatively high affinity for human receptor angiotensin-converting enzyme 2, with structural analysis identifying the R493Q reverse mutation as the key determinant. Pseudovirus infection and antibody neutralization assays demonstrated that RE.2.2 exhibited a distinct neutralization profile compared to contemporaneous dominant subvariants. Notably, several antibodies that previously lacked neutralizing activity (e.g., S2K146 and L4.65) to other subvariants regained neutralizing potency against RE.2.2, which was associated with key mutations including G446D. Profiling of RE.2.2 RBD binding to ACE2 orthologs across species showed no significant difference in species tropism from the representative Omicron BA.1. Importantly, RE.2.2 exhibits the newly emerged N-linked glycosylation at spike protein N529 (absent in all other subvariants), a modification potentially associated with immune evasion or spike protein conformational dynamics. In addition, we corroborated the “O-follow-N” glycosylation observation as previously reported, where O-linked glycans preferentially localize near N-glycosylation sites, implying coordinated glycan organization as an extra layer of spike regulation. These findings illuminate the evolutionary characteristics, functional changes, and the constrained virus immune escape of BA.3.2.2 (RE.2.2), providing critical insights into antibody development and variant surveillance.

Source: 

Link: https://doi.org/10.1073/pnas.2614163123

____

The First 100 Days of Five #Ebola #Outbreaks — #DRC, #Uganda, and West #Africa, 2007–2026 (MMWR, Sept. 15 '26)

 

Summary

    ° What is already known about this topic?

        § The Democratic Republic of the Congo (DRC) is experiencing its largest and deadliest Ebola disease outbreak, which is also the largest Ebola outbreak caused by Bundibugyo virus and the second largest Ebola outbreak worldwide.

    ° What is added by this report?

        § The 2026 Ebola outbreak resulted in 5,458 confirmed cases and 2,606 deaths in DRC in the first 100 days after initial detection, indicating rapid growth. No previous Ebola outbreak caused >800 cases during the first 100 days.

    ° What are the implications for public health practice?

        § This Ebola outbreak appears to be expanding faster than any previously documented Ebola outbreak, with seven times as many cases 100 days after initial detection than the 2014 Ebola outbreak in West Africa, the largest outbreak worldwide. Urgent implementation of public health interventions to identify cases, trace contacts, and limit transmission are needed to bring the outbreak under control.

Abstract

The first 100 days after identification of an outbreak are important to understanding transmission dynamics, impact of early public health interventions, and trajectory of potential future cases and deaths. A large Ebola disease outbreak in the Democratic Republic of the Congo (DRC), which has become the country’s largest and deadliest, is ongoing. To better understand the current outbreak, this report compared metrics from the first 100 days of this outbreak with those of four past Ebola outbreaks. The historic outbreaks of Ebola disease selected for this comparison include the two largest (the 2014 outbreak in West Africa and a 2018 outbreak in DRC), and the only two previous outbreaks caused by Bundibugyo virus (the 2007 outbreak in Uganda and the 2012 outbreak in DRC). This activity was reviewed by CDC, deemed not research, and conducted consistent with applicable federal law and CDC policy.*

Source: 

Link: http://dx.doi.org/10.15585/mmwr.mm7537e1

____

#Nuclear #Conflict in Eastern #Europe: #Climate #disruption and #Radiological fallout

 

Abstract

Geopolitical tensions in Eastern Europe underscore the urgency of addressing the climatic and radiological consequences of a regional nuclear conflict. Using an Earth System Model, we simulate a hypothetical nuclear conflict at the Ukraine-Russia border that releases 5 Teragram (Tg; 5 million tons) of black carbon (BC), the dominant driver of the post-detonation climate response, into the stratosphere. We adopt the 5 Tg BC post-detonation emission scenario because it is a widely modelled scenario for a “limited” regional nuclear conflict (typically India–Pakistan), enabling a direct comparison with prior studies. The extended stratospheric lifetime of BC induces hemispheric climate disruption: the Northern Hemisphere cools by ~1 °C in year-1, with anomalies of −5 °C in Russia and −4 °C in the United States; surface solar radiation declines by ~30 W m−2 over the US; and precipitation decreases by ~40% across mid-latitude croplands. Stratospheric warming alters subtropical and polar jets, displacing the Intertropical Convergence Zone ~2–6° southward, delaying climate recovery by ~6 years. Long-lived radionuclides transported with BC disperse globally, with ~40% depositing in the Southern Hemisphere. These findings underscore the importance of nuclear-risk reduction and provide a robust benchmark for food-security and humanitarian-impact assessments.

Source: 

Link: https://www.nature.com/articles/s44407-026-00064-7

____

#Habitat-Mediated #Spillover #Risk of #Andes #Hantavirus in Oligoryzomys longicaudatus: A Mechanistic Eco-Epidemiological Model

 

Abstract

Andes hantavirus (ANDV) is a rodent-borne orthohantavirus associated with hantavirus cardiopulmonary syndrome in southern South America. Its maintenance and spillover risk depend on the ecology of its principal reservoir, Oligoryzomys longicaudatus, and on environmental changes that alter habitat availability, host abundance, and human–rodent interfaces. We developed a mechanistic eco-epidemiological model that couples effective habitat cover to an SIR framework for ANDV transmission in O. longicaudatus. Habitat degradation and compensatory restoration modify rodent carrying capacity, natality, and the force of infection, which depends on infected host load relative to instantaneous ecological capacity. We derived the habitat equilibrium, the basic reproduction number ℛ0, and the time-dependent effective reproduction number ℛ𝑒(𝑡) and evaluated infection-burden and threshold indicators across degradation-restoration scenarios. The  analysis shows that ℛ0 is independent of equilibrium habitat cover because susceptible abundance scales with carrying capacity at the disease-free  equilibrium. In contrast, ℛ𝑒(𝑡), cumulative incidence, and infected load depend on transient habitat-mediated crowding. Restoration increases reservoir abundance and absolute infection burden, whereas degradation can reduce abundance while increasing crowding-driven transmission pressure and prolonging supercritical windows. These results identify ecological conditions under which habitat change may intensify reservoir infection pressure and guide One Health surveillance at human–rodent interfaces.

Source: 

Link: https://www.mdpi.com/1999-4915/18/9/1024

____

Co-occurrence #networks from #wetland #bird #surveys predict #H5N1 genetic similarity between wild birds with strong effects of time, space and viral clustering

 

Abstract

The emergence of zoonotic and epizootic diseases has had devastating consequences for human and animal health, including wildlife conservation. Yet, surveillance of multi-host disease systems is particularly challenging due to complex transmission pathways across many species. Social network analysis has been applied to simple transmission systems, but empirical applications to wild, multi-species systems are scarce. Here, we combined high pathogenicity avian influenza (HPAI) viral genomes, a zoonotic virus of pandemic potential, with a large citizen-science database of wild bird co-occurrence to test how multi-species social network structure predicts transmission dynamics. We linked viral genetic distance, 20,103 pairwise comparisons between 214 unique genomes from 172 dyads of 20 host species, to co-occurrence network metrics for those species. Both relative species association and raw co-occurrence frequency predicted lower maximum viral genetic divergence, more similar viruses between more associated species, beyond what would be expected through random mixing and independently of sequencing effort. Time and space between samples were also strong predictors of genetic similarity. Our results suggest that network models can be used to detect pathogen transmission through communities of wild birds, offering real prospects for wildlife disease surveillance and prediction.

Competing Interest Statement

The authors have declared no competing interest.

Source: 

Link: https://www.biorxiv.org/content/10.1101/2025.06.17.659947v5

____

#Pathogenesis and natural history of the #Bundibugyo species of #Orthoebolavirus in nonhuman #primates

 

Abstract

The current outbreak of Bundibugyo virus (BDBV) in Africa is a global public health concern particularly as there are no licensed medical countermeasures (MCM). Well characterized animal models that accurately replicate human BDBV infection are needed to develop effective MCM. We exposed 21 cynomolgus monkeys (CM) to BDBV to examine the progression and natural history of BDBV disease (BVD). BVD was more protracted than reported for Ebola and Sudan infection in CM with a lower lethality rate of 67% consistent with lower human BVD mortality rates. IHC and spatial proteomics identified CD209+, CD68+, and/or HLA-DR+ macrophages and dendritic cells as early targets of BDBV. These infected cells frequently colocalized with fibrin and infiltrating MPO+ neutrophils and S100A9+ myeloid-derived suppressor cells, consistent with the development of an active inflammatory response and early coagulopathy. Transcriptomic and proteomic analyses of the circulating immune response correspondingly reflected a cytokine-driven hyperinflammatory state in CM that succumbed to disease. Surviving animals resolved systemic inflammation by the study endpoint; however, BDBV antigen was identified in immune privileged tissues with lesion-associated inflammation aligning with known post-Ebola sequela in humans. This data should assist in identifying weaknesses in the disease course that can be exploited to develop new MCM.

Competing Interest Statement

The authors have declared no competing interest.

Funder Information Declared

National Institute of Allergy and Infectious Diseases, https://ror.org/043z4tv69, U19AI109945

The University of Texas Medical Branch at Galveston, https://ror.org/016tfm930, N/A

Source: 

Link: https://doi.org/10.64898/2026.08.10.743937

____

Assessment of immune #response induced by ChAdOx1 nCoV-19, Sputnik V, and BNT162b2 #vaccines during #COVID19 #outbreak in #Mexican population: Gene expression of the #cytokine storm

 

Highlights

    • The molecular immune response triggered by vaccines against COVID-19 was analyzed.

    • The evaluated genes were ACE2, CD79B, TMPRSS2, CTSB, FCGR3A and MB-1.

    • These vaccines induce a protective immune response through various mechanisms.

    • Vaccines regulate the immune response through pro- and anti-inflammatory cytokines.

Abstract

Introduction

COVID-19 vaccines using different technological platforms may induce distinct molecular responses. Characterizing gene-expression patterns after vaccination and in fatal COVID-19 may identify pathways associated with vaccination and severe disease.

Objective

To compare immune-, inflammatory-, and SARS-CoV-2-entry-related gene expression after AstraZeneca, Pfizer, or Sputnik V vaccination and with unvaccinated fatal COVID-19.

Materials and methods

Eighty Mexican adults were included: AstraZeneca (n = 19), Pfizer (n = 20), Sputnik (n = 21), and unvaccinated fatal COVID-19 (n = 20). Expression of 11 genes was measured by qPCR at days 30 (D30) and 60 (D60) after vaccination.

Statistical analysis

Longitudinal differences were analyzed by two-way repeated-measures ANOVA. Comparisons with fatal COVID-19 were exploratory. Benjamini–Hochberg correction controlled false discovery rate at 5%.

Results

No differences among vaccines were detected at D30. At D60, IL-10, IL-2, and CD79A differed among selected vaccine groups. Longitudinally, FCGR3A decreased in AstraZeneca and Sputnik, ACE2 decreased in Pfizer and Sputnik, and TMPRSS2 increased in Sputnik. Fatal COVID-19 showed predominantly higher expression of several genes than vaccinated groups. Notably, IL-2 and ACE2 were consistently higher in fatal COVID-19 than in all vaccinated groups at both time points.

Discussion and conclusions

Post-vaccination transcriptional profiles were dynamic, with selected differences emerging at D60, whereas fatal COVID-19 exhibited a distinct profile characterized predominantly by higher expression of immune-, inflammatory-, and viral-entry-related genes. Consistent IL-2 and ACE2 differences highlight molecular pathways potentially associated with severe disease. The observational design, however, precludes causal attribution to vaccination.

Perspectives

Longitudinal studies with appropriate controls are needed to establish the biological significance of these transcriptional patterns.

Source: 

Link: https://doi.org/10.1016/j.meegid.2026.106025

____

#Coronavirus Disease Research #References (AMEDEO, September 13 '26)

 

Eur J Radiol

1. GARCIA-HIDALGO C, Naval-Baudin P, Garcia-Garcia JI, Viveros-Castano M, et al
   Dynamic susceptibility contrast perfusion-weighted imaging (DSC-PWI) vascular and metabolic biomarkers for presurgical diagnosis of adult brain tumors across different acquisition parameters.
   Eur J Radiol. 2026;205:113218.
   PubMed         Abstract available
   
   

   
   J Infect

2. QIAN J, Zhang Z, Zhang L
   SARS?CoV?2 spike CTD suppresses host metabolism but restricts viral entry through a PDZ?dependent trade?off.
   J Infect. 2026 Sep 11:106857. doi: 10.1016/j.jinf.2026.106857.
   PubMed        
   
   
3. MAZARAKIS N, Toh ZQ, Neal E, Nguyen C, et al
   Corrigendum to 'Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia' [J Infect 92 (2026)/106727].
   J Infect. 2026;93:106851.
   PubMed        
   
   
4. MAZARAKIS N, Toh ZQ, Neal E, Bright K, et al
   Corrigendum to "The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose" [J Infect 90 (2025)/106447].
   J Infect. 2026;93:106850.
   PubMed        
   
   

   
   J Med Virol

5. TIKHONOVA IV, Dyukina AR, Grinevich AA, Tutukina MN, et al
   Immunological Properties of SARS-CoV-2 S and M Protein Fragments and Their Effects on Respiratory Burst in Human Neutrophils.
   J Med Virol. 2026;98:e71151.
   PubMed         Abstract available
   
   
6. SREELAKSHMI PR, Wagh P, Sarje P, Shinde T, et al
   Distinct Cytokine Signatures and Antibody Neutralization Capacity Differentiate Post-Acute Sequelae of COVID-19 From Recovered Individuals Despite Comparable T Cell Responses.
   J Med Virol. 2026;98:e71145.
   PubMed         Abstract available
   
   

   
   J Travel Med

7. VAN GENDEREN PJJ, van Sprang ENM
   Artificial Intelligence and Complementary Digital Health Technologies Across the Travel Medicine Continuum: A Narrative Review.
   J Travel Med. 2026 Sep 9:taag082. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Virol

8. KIRK J, Sives S, Rayment A, Tappin A, et al
   Spike protein derived from an apathogenic IBV strain confers attenuated phenotype to a nephropathogenic IBV strain.
   J Virol. 2026 Sep 10:e0110326. doi: 10.1128/jvi.01103.
   PubMed         Abstract available
   
   
9. LIU M, Duong MTH, Laocharoensuk T, Aryal B, et al
   Mutations in the macrodomain 1 of nsp3 attenuate PEDV virulence in vivo without impairing in vitro replication.
   J Virol. 2026 Sep 9:e0125126. doi: 10.1128/jvi.01251.
   PubMed         Abstract available
   
   
10. YU R, Zhang L, Zhou P, Zhang Z, et al
    Low-pH-induced conformational changes in the spike protein promote porcine deltacoronavirus infection by enhancing viral binding efficiency to the porcine aminopeptidase receptor.
    J Virol. 2026 Sep 9:e0116826. doi: 10.1128/jvi.01168.
    PubMed         Abstract available
    
    
11. ALVARADO RE, Chen J, Lokugamage KG, Zhou Y, et al
    Antagonism of stress granules is key to SARS-CoV-2 infection and pathogenesis.
    J Virol. 2026 Sep 8:e0099226. doi: 10.1128/jvi.00992.
    PubMed         Abstract available
    
    
12. YAO Z, Zhu Y, Liu N, Hu Y, et al
    The alpha-helix-facilitating amino acid sequence EAAAK dramatically increases the antiviral activity of SARS-CoV-2 fusion-inhibitory peptides via the endosome fusion pathway.
    J Virol. 2026 Sep 8:e0106726. doi: 10.1128/jvi.01067.
    PubMed         Abstract available
    
    

    
    Life Sci

13. HAN D, Beurel E
    The spike protein S1 of SARS-CoV-2 promotes Th17 cell-dependent stress-induced depressive-like behaviors in mice.
    Life Sci. 2026 Sep 8:124672. doi: 10.1016/j.lfs.2026.124672.
    PubMed         Abstract available
    
    

    
    N Engl J Med

14. HAYDEN FG, Sax PE
    Ensitrelvir for Covid-19 Postexposure Prophylaxis. Reply.
    N Engl J Med. 2026;395:1039.
    PubMed        
    
    
15. SUZUKI J, Imai H, Endo S
    Ensitrelvir for Covid-19 Postexposure Prophylaxis.
    N Engl J Med. 2026;395:1039.
    PubMed        
    
    

    
    Travel Med Infect Dis

16. TIMPERLEY EK, Swithenbank L, Beeching NJ, Tang E, et al
    General physicians still fail to take travel histories.
    Travel Med Infect Dis. 2026 Sep 9:103021. doi: 10.1016/j.tmaid.2026.103021.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, September 13 '26)

 

Antimicrob Agents Chemother

1. PENG Z, Yuan H, Huang J, Lin X, et al
   A novel ursodeoxycholic acid derivative exhibits broad-spectrum antiviral activity against influenza A virus and coronaviruses by multiphasic disruption of the viral life cycle.
   Antimicrob Agents Chemother. 2026 Sep 9:e0028426. doi: 10.1128/aac.00284.
   PubMed         Abstract available
   
   

   
   BMC Pediatr

2. BOZZOLA E, Piccotti E, D'Auria E, Trapani S, et al
   RESPIRIAMO - Italian hospital surveillance for lower respiratory tract infections: a multicenter retrospective cohort study of respiratory syncytial virus-associated hospitalizations in children under 2 years of age.
   BMC Pediatr. 2026;26:853.
   PubMed         Abstract available
   
   

   
   J Infect

3. ZHU X, Deng Y, Xiao G, Zhang J, et al
   Re-emergence of H10N3 Avian Influenza Viruses in China: Evolutionary Dynamics and Emerging Zoonotic Risk.
   J Infect. 2026 Sep 7:106848. doi: 10.1016/j.jinf.2026.106848.
   PubMed        
   
   

   
   J Virol Methods

4. EZEANYAEGBU CN, Toledo NP, Corkum CP, Nelder M, et al
   Evaluation of one-step amplicon-based targeted enrichment for SARS-CoV-2 whole-genome sequencing using the Midnight amplicon scheme.
   J Virol Methods. 2026;346:115448.
   PubMed         Abstract available
   
   
5. KAZEMIAN S, Pedroza S, Santana-Pereira ALR, Neasham PJ, et al
   An enhanced multisegment RT-PCR method for influenza A virus sequencing: Improved performance and reduced preparation time over traditional methods.
   J Virol Methods. 2026;347:115453.
   PubMed         Abstract available
   
   

   
   PLoS Comput Biol

6. QUILTY BJ, Chapman LAC, Munday JD, Wong KLM, et al
   Disentangling the drivers of heterogeneity in SARS-CoV-2 transmission from data on viral load and daily contact rates.
   PLoS Comput Biol. 2026;22:e1014715.
   PubMed         Abstract available
   
   
7. SONG P, de Vlas SJ, Emery T, Coffeng LE, et al
   Mapping spatial colleague connectivity patterns from individual-level registry data to inform regional pandemic interventions.
   PLoS Comput Biol. 2026;22:e1014721.
   PubMed         Abstract available
   
   
8. PANT B, Lalovic M, Kiss IZ, Santillana M, et al
   The paradox of neglecting changes in behavior: How standard epidemic models misestimate both transmissibility and final epidemic size.
   PLoS Comput Biol. 2026;22:e1014746.
   PubMed         Abstract available
   
   
9. YUAN Z, Zhang X, Lin G, Zou Q, et al
   AET5: A transcriptome-guided molecular generation framework with contrastive self-supervised learning.
   PLoS Comput Biol. 2026;22:e1014703.
   PubMed         Abstract available
   
   
10. BENHAMOU W, Howerton E, Park SW, Viboud C, et al
    Leveraging perturbations to infer the population dynamics of human rhinovirus and interaction of influenza A virus.
    PLoS Comput Biol. 2026;22:e1014784.
    PubMed         Abstract available
    
    

    
    PLoS Med

11. LENGLART L, Titomanlio L, Alberti I, Almeida L, et al
    Association between nirsevimab coverage and pediatric emergency department visits for bronchiolitis in 12 European countries: An interrupted time-series analysis.
    PLoS Med. 2026;23:e1005223.
    PubMed         Abstract available
    
    

    
    PLoS One

12. KWON K, Jang CY, Kim W, Son J, et al
    Kinetics of the PASC Index in Long COVID.
    PLoS One. 2026;21:e0357670.
    PubMed         Abstract available
    
    
13. BATTU S, Moore AR, Lebold K, Pacheco-Navarro A, et al
    Outcomes of immunocompromised and non-immunocompromised patients in the ICU diverge late in the pandemic.
    PLoS One. 2026;21:e0357181.
    PubMed         Abstract available
    
    
14. JI M, Dong H, Xu Y, Wang Y, et al
    Development of a multiplex real-time PCR assay with fluorescence probe-melting-curve analysis for one-tube detection of respiratory pathogens.
    PLoS One. 2026;21:e0357377.
    PubMed         Abstract available
    
    
15. GONG X, Liu L, Lu Y, Zhang G, et al
    Sleepless in America: A social sensing study of pandemic-era sleeplessness using nighttime social media data.
    PLoS One. 2026;21:e0356547.
    PubMed         Abstract available
    
    
16. BHATIA A, Elser J, Carrell SJ, Kronmiller B, et al
    Correlation assessment of SARS-CoV-2 variants and their subvariants present in clinical and wastewater samples in Oregon, USA (February 7, 2021 - February 26, 2022) using the Freyja bioinformatics approach.
    PLoS One. 2026;21:e0357591.
    PubMed         Abstract available
    
    
17. MOHD YUSOFF H, Yew SQ, Mohd Nawi A, Mohd Tohit N, et al
    Prevalence and risk factors of adverse work outcomes among manufacturing workers with Long COVID in Malaysia - A nationwide study.
    PLoS One. 2026;21:e0357125.
    PubMed         Abstract available
    
    
18. VALDES-LOPEZ JF, di Filippo D, Penagos S, Hernandez-Sarmiento LJ, et al
    SARS-CoV-2 infection induces functional impairment of vitamin D receptor signaling to drive interleukin 6-dependent hyperinflammation in mononuclear phagocytes.
    PLoS One. 2026;21:e0357030.
    PubMed         Abstract available
    
    
19. AMARSANAA J, Nguyen TXT, Khan MSR, Kadoya Y, et al
    The dynamics of loneliness: A longitudinal exploration of transitions in Japan across the COVID-19 period, 2020-2024.
    PLoS One. 2026;21:e0358269.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

20. LI L, Nguyen L, Qu H, Wu Q, et al
    Increased receptor binding and spike glycosylation, remodeled immune escape of surging SARS-CoV-2 subvariant BA.3.2.2/RE.2.2/Cicada.
    Proc Natl Acad Sci U S A. 2026;123:e2614163123.
    PubMed         Abstract available
    
    

    
    Vaccine

21. BUCKLIN R, Gauthreaux N, Faber E, Askelson N, et al
    Listening to micropolitan community leaders to support pandemic response efforts.
    Vaccine. 2025;60 Suppl 1:127255.
    PubMed         Abstract available
    
    
22. HOLLIDAY RC, Darkwa A, Brooks GA, Akintobi TH, et al
    Developing counter-narratives to address COVID-19 misinformation among 18-24 year olds in community and campus settings.
    Vaccine. 2025;60 Suppl 1:127135.
    PubMed         Abstract available
    
    
23. HEIMAN SL, Geiger N
    Overestimation of racial ingroup worry about the COVID-19 vaccine and medical racism.
    Vaccine. 2026;91:129046.
    PubMed         Abstract available
    
    
24. DUTTA S, Ngemera D, Jaillard P, Juneja S, et al
    Lessons learnt from one-year cold chain support for COVID-19 vaccination in 5 middle income countries of North Africa.
    Vaccine. 2026;91:128994.
    PubMed         Abstract available
    
    
25. CAMPBELL STATLER M, Bishop-Royse J, Sampson AT, Martin M, et al
    Heterogeneity among the vaccine hesitant: A secondary analysis of the national CEAL Common Survey data.
    Vaccine. 2026;91:129024.
    PubMed         Abstract available
    
    
26. KIM SJ, Kim HW, Son SE, Song JH, et al
    Wuhan-ancestral multi-antigen SARS-CoV-2 virus-like particles protect against the omicron sublineage JN.1 variant.
    Vaccine. 2026;91:129059.
    PubMed         Abstract available
    
    
27. FAHFOUHI Y, Fievez S, Cohen R, Levy C, et al
    A health-economic assessment of the impact of different RSVpreF maternal vaccine strategies to prevent RSV infections among young infants, in France: EPIPACT.
    Vaccine. 2026;91:129036.
    PubMed         Abstract available
    
    
28. BERIKOPOULOU MM, Tatsi EB, Siahanidou T, Michos A, et al
    Systematic review of the mutations in the active antigenic site O of the prefusion F protein of the Respiratory Syncytial Virus (RSV) following the implementation of monoclonal antibody prophylaxis.
    Vaccine. 2026;91:129069.
    PubMed         Abstract available
    
    
29. NUNES JPDS, Daher IP, Pires ADS, Yamamoto MM, et al
    Synergistic effect of AddaS03 and poly I:C adjuvants on antibody titers and Th1-biased T cell responses following RBD vaccination in BALB/c mice.
    Vaccine. 2026;91:129073.
    PubMed         Abstract available
    
    
30. MONOI A, Endo A, Kriznar M, Suzuki M, et al
    Comparing the potential impacts of seasonal immunisation against year-round immunisation to prevent RSV infant hospitalisations in Japan: A modelling study.
    Vaccine. 2026;91:129079.
    PubMed         Abstract available
    
    
31. SCHRARSTZHAUPT IN, Diaz-Quijano FA
    Effectiveness of COVID-19 vaccination schedules against severe COVID-19 in children aged 6 months to 4 years in Brazil: A population-based cohort study (2023-2024).
    Vaccine. 2026;91:129096.
    PubMed         Abstract available
    
    
32. ALAMI A, Lewis M, El-Chaar D, Walker M, et al
    Maternal vaccination with RSVpreF and risk of hypertensive disorders of pregnancy: a systematic review and meta-analysis.
    Vaccine. 2026;91:129070.
    PubMed         Abstract available
    
    
33. DENG L, Ye X, Chen X, Hu X, et al
    Secretory expression of tetrameric neuraminidase enhanced by signal peptide optimization elicits robust immunity against influenza infection in mice.
    Vaccine. 2026;92:129118.
    PubMed         Abstract available
    
    
34. SANBORN J, Robertson MM, Penrose K, Rane M, et al
    Gaps between willingness and uptake of influenza and COVID-19 vaccines during the 2025-26 respiratory virus season in a U.S. adult cohort.
    Vaccine. 2026;92:129126.
    PubMed         Abstract available
    
    
35. LU J, Ouyang Z, Huang F, Xie X, et al
    Real-world effectiveness of the influenza vaccine among school-aged children in Shenzhen, China, 2024-2025 season: A test-negative design study.
    Vaccine. 2026;92:129100.
    PubMed         Abstract available
    
    
36. THAKKAR V, Aryan Y, Gautam S, Joshi R, et al
    Influence of vaccine delivery route on immune imprinting in influenza vaccination.
    Vaccine. 2026;92:129109.
    PubMed         Abstract available
    
    
37. TORAIH EA, Hussein MH, Thomas SJ, Aiash H, et al
    Cardiac outcomes following SARS-CoV-2 infection versus BNT162b2 vaccination in adolescents and young adults: a cohort study of 4 million individuals.
    Vaccine. 2026;91:129001.
    PubMed         Abstract available
    
    
38. CABURNAY CA, Fu QJ, Carter T, Butler T, et al
    Identification of best outreach strategies and delivery modalities for population subgroups for COVID-19 vaccination.
    Vaccine. 2026;60 Suppl 1:128721.
    PubMed         Abstract available
    
    
39. CANACA G, Vicuna B, Hess JM, Cruz TH, et al
    From engagement to ownership: a qualitative study of a community-academic partnership to promote COVID-19 vaccine confidence among Latino/Hispanic communities in New Mexico.
    Vaccine. 2026;60 Suppl 1:128583.
    PubMed         Abstract available
    
    
40. STIEHL E, Negrete M, Flores G, Federmeyer L, et al
    Empowering communities during the COVID-19 pandemic: insights from trusted messengers about their work addressing COVID-19 vaccine hesitancy.
    Vaccine. 2026;60 Suppl 1:128559.
    PubMed         Abstract available
    
    
41. NUNO T, Soto S, Sepulveda R, Sierra LA, et al
    The Arizona prevention research center vaccine confidence network: A Mobile health unit intervention and survey results of barriers and facilitators to COVID-19 vaccination.
    Vaccine. 2025;60 Suppl 1:127970.
    PubMed         Abstract available
    
    
42. HARA-HUBBARD KK, Beaulieu A, Mendiola A, Gandhi P, et al
    Strategies for addressing COVID-19 vaccine equity with intermediaries, prevention research centers, and the vaccine confidence network.
    Vaccine. 2025;60 Suppl 1:127847.
    PubMed         Abstract available
    
    
43. CHUVILEVA YE, Kuiper NM, Ramakrishnan A, Goodman K, et al
    Weaving a public health network: Process and results from an evaluation of CDC's Prevention Research Centers Vaccine Confidence Network.
    Vaccine. 2025;60 Suppl 1:127636.
    PubMed         Abstract available
    
    
44. ALMUKHTAR S, McWhirter N, Mendiola A, Samuel S, et al
    Exploring lingering COVID-19 vaccine hesitancy in three diverse U.S. states: Alabama, Illinois, and Texas.
    Vaccine. 2025;60 Suppl 1:127664.
    PubMed         Abstract available
    
    
45. BEAULIEU A, LaMonaca K, Higginbottom J, Foster J, et al
    Utilizing the Program Impact Pathways framework for improving COVID-19 vaccine confidence and uptake: demonstrations of multi-sector collaboration from two geographies in Connecticut.
    Vaccine. 2025;60 Suppl 1:127623.
    PubMed         Abstract available
    
    
46. JEFFERS A, Kuiper NM, Ramakrishnan A, Swarna H, et al
    Building trust in community-academic partnerships: Strategies for enhancing vaccine confidence and demand - Lessons from Prevention Research Centers.
    Vaccine. 2025;60 Suppl 1:127624.
    PubMed         Abstract available
    
    
47. MCGEE RE, Barrett DA, Bednarczyk RA, Grant-Whitlock M, et al
    Engaging rural and non-Hispanic Black persons in conversations about the COVID-19 vaccine: a process evaluation of a natural helper intervention.
    Vaccine. 2025;60 Suppl 1:127587.
    PubMed         Abstract available
    
    
48. BORG A, Goulding M, Minkah P, Perrone D, et al
    Promotion of COVID-19 vaccination for youth and families in Worcester, Massachusetts: a Diffusion of Innovations approach.
    Vaccine. 2025;60 Suppl 1:127586.
    PubMed         Abstract available
    
    
49. SAVAS LS, Cuccaro P, Zhang K, Hernandez R, et al
    Factors influencing COVID-19 vaccine uptake among vulnerable communities in Texas: Perceptions of 2-1-1 helpline callers.
    Vaccine. 2025;60 Suppl 1:127554.
    PubMed         Abstract available
    
    
50. TOTZKAY D, Fraustino JD, Costello LM, Jarrett T, et al
    Building on West Virginia's innovative COVID-19 public health communication: associations between vaccination beliefs and vaccination messaging, partisanship, and social vulnerability.
    Vaccine. 2025;60 Suppl 1:127555.
    PubMed         Abstract available
    
    
51. O'CONNOR MH, Nyman AL, Ali S, Rothenberg R, et al
    Increasing vaccine uptake in a refugee resettlement community with high social vulnerability.
    Vaccine. 2025;60 Suppl 1:127552.
    PubMed         Abstract available
    
    
52. STIEHL E, Borg A, Cullen JP, Mendiola A, et al
    Engaging trusted messengers in public health response: Key strategies to building community trust among CDC'S prevention research center's vaccine confidence network.
    Vaccine. 2025;60 Suppl 1:127474.
    PubMed         Abstract available
    
    
53. HARA-HUBBARD KK, Flores Moreno MG, Sanchez M, Abdi N, et al
    The partnership for vaccine confidence: community-academic partnerships to promote COVID-19 vaccines to underserved urban and rural communities using the listen, plan, act, evaluate process.
    Vaccine. 2025;60 Suppl 1:127487.
    PubMed         Abstract available
    
    
54. MALLICK K, Handunge VL, Emmons KM, Blondet L, et al
    Engaging a community health ambassador model to promote COVID-19 vaccine in three Massachusetts communities.
    Vaccine. 2025;60 Suppl 1:127464.
    PubMed         Abstract available
    
    

    
    Virology

55. ISHIGAKI H, Otaki K, Kitagawa N, Ishida H, et al
    Pathogenicity of SARS-CoV-2 Omicron subvariants JN.1, EG.5.1, and BA.2.86.1 in immunologically naive cynomolgus macaques.
    Virology. 2026;624:111036.
    PubMed         Abstract available
    
    
56. LIU Z, Fan M, Zheng Y, Zeng Y, et al
    Transcriptome screening identifies circRNA-INSR as a novel host factor associated with avian influenza virus replication.
    Virology. 2026;625:111072.
    PubMed         Abstract available
    
    
57. MILLER AK, Heremia L, Waller SJ, Blanchard SL, et al
    Evaluating sampling strategies for the detection of avian influenza viruses in the environment.
    Virology. 2026;625:111069.
    PubMed         Abstract available
    
    

    
    Virus Res

58. ZHAO Y, Fan H
    Clinical impact of baloxavir-induced PA I38T/M substitutions in diverse influenza populations: a systematic review and meta-analysis.
    Virus Res. 2026;373:199797.
    PubMed         Abstract available

Respiratory #pandemic #risk in the #Anthropocene: A #OneHealth #framework and #GISRS+ agenda

 

Highlights

    • Respiratory pandemics are now a structural feature of the Anthropocene.

    • H5Nx and SARS-related CoVs are identified as leading pandemic candidates.

    • A geographic mismatch exists between spillover risk and surveillance.

    • A multidimensional GISRS+ agenda is proposed for proactive One Health.

Abstract

Recent epidemics and pandemics caused by respiratory viruses, alongside the animal panzootic spread of highly pathogenic avian influenza A(H5Nx), have become a structural feature of the Anthropocene, yet responses remain largely reactive. This review integrates findings from WHO's Global Influenza Surveillance and Response System (GISRS) and related surveillance data (2000–2024), epidemiological studies of influenza A virus, SARS-CoV, MERS-CoV, SARS-CoV-2, and H5Nx, and One Health literature. We examine major groups of respiratory viruses and identify mismatches between risk and surveillance by focusing on spillover potential from animal hosts, human-to-human transmission and its controllability, and Anthropocene characteristics that increase epidemic risk. The analysis indicated that SARS-related coronaviruses and influenza A viruses, particularly H5Nx, are among the leading candidates based on currently available evidence because they have large reservoirs in animal hosts and spillover to humans is highly probable. The previous presymptomatic spread of SARS-CoV-2 and recent mammalian adaptation in H5N1 clade 2.3.4.4b highlight limitations of the traditional symptom-based and pathogen-specific surveillance system. Spillover events tend to occur in tropical and subtropical regions in low- and middle-income countries, but most genomic surveillance is in high-income countries. We propose interventions that address the upstream, midstream, downstream processes of epidemics. Upstream interventions are primary prevention measures related to land use, livestock, wildlife, and urban environments; midstream interventions are GISRS+-based pathogen-agnostic genomic and metagenomic early warning systems triggered by One Health; and downstream interventions include vaccines, antivirals, non-pharmaceutical interventions, and engineering with equity-centred global governance and sustainable financing.

Source: 

Link: https://doi.org/10.1016/j.onehlt.2026.101553

____